Literature DB >> 23218156

Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.

Albertine A Scheltema Beduin1, Marije Swets, Marise Machielsen, Nikie Korver.   

Abstract

OBJECTIVE: To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking clozapine, olanzapine, or risperidone or taking no antipsychotic medication.
METHOD: Baseline data of the Genetic Risk and Outcome of Psychosis study were collected between April 2005 and October 2008. We conducted a naturalistic cross-sectional study of 543 patients with schizophrenia and related disorders, who were recruited from multiple mental health centers, including inpatient and outpatient clinics, across The Netherlands. The patients met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and were taking no antipsychotic medication or taking clozapine, olanzapine, or risperidone. OCS severity was measured with the Yale-Brown Obsessive Compulsive Scale. We compared patients to a sample of 575 healthy controls.
RESULTS: Prevalence of OCS in patients was significantly higher than in the control sample, 23.4% versus 4.9% (χ(2) = 73.8, P < .001). Patients taking clozapine reported OCS significantly more often during the last week (38.9%), when compared to patients taking olanzapine (20.1%, χ(2) = 10.02, P = .002) or risperidone (23.2%, χ(2) = 5.96, P = .015) and patients taking no antipsychotics (19.6%, χ(2) = 8.20, P = .004). Patients taking clozapine for 6 months or longer reported OCS significantly more often than patients taking clozapine for less than 6 months, 47.3% versus 11.8% (χ(2) = 6.89, P = .009).
CONCLUSIONS: Treatment with clozapine in patients with schizophrenia is associated with a higher prevalence of OCS, especially when patients have been taking clozapine for 6 months or longer. We cannot rule out the possibility that this association is related to illness characteristics. Patients treated with risperidone or olanzapine or without treatment with antipsychotic medication had comparable prevalence of OCS, all significantly higher than the control sample. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218156     DOI: 10.4088/JCP.11m07164

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

Review 1.  Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

Authors:  Trehani M Fonseka; Margaret A Richter; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 2.  Anxiety in Patients with Schizophrenia: Epidemiology and Management.

Authors:  Henk Temmingh; Dan J Stein
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

Review 3.  Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.

Authors:  Gregory Kruse; Bruce J O Wong; Mei Sheng Duh; Patrick Lefebvre; Marie-Hélène Lafeuille; John M Fastenau
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

4.  Differential diagnosis of obsessive-compulsive symptoms from delusions in schizophrenia: A phenomenological approach.

Authors:  Panagiotis Oulis; George Konstantakopoulos; Lefteris Lykouras; Panayiota G Michalopoulou
Journal:  World J Psychiatry       Date:  2013-09-22

5.  Obsessive-Compulsive Disorder, Psychosis, and Bipolarity: A Longitudinal Cohort and Multigenerational Family Study.

Authors:  Martin Cederlöf; Paul Lichtenstein; Henrik Larsson; Marcus Boman; Christian Rück; Mikael Landén; David Mataix-Cols
Journal:  Schizophr Bull       Date:  2014-12-15       Impact factor: 9.306

6.  Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness.

Authors:  Tommaso Accinni; Marianna Frascarelli; Francesco Ghezzi; Alessia Panzera; Antonino Buzzanca; Martina Fanella; Carlo Di Bonaventura; Luca Carlone; Nicoletta Girardi; Massimo Pasquini; Fabio Di Fabio
Journal:  Clin Case Rep       Date:  2021-05-24

7.  Evidence for a Shared Etiological Mechanism of Psychotic Symptoms and Obsessive-Compulsive Symptoms in Patients with Psychotic Disorders and Their Siblings.

Authors:  Marije Swets; Frank Van Dael; Sabine Roza; Robert Schoevers; Inez Myin-Germeys; Lieuwe de Haan
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

8.  Cognitive-behavioural therapy for obsessive-compulsive disorder co-occurring with psychosis: Systematic review of evidence.

Authors:  Antonio Tundo; Roberta Necci
Journal:  World J Psychiatry       Date:  2016-12-22

9.  Prevalence of comorbid anxiety disorders in schizophrenia.

Authors:  Chandra Kiran; Suprakash Chaudhury
Journal:  Ind Psychiatry J       Date:  2016 Jan-Jun

10.  Psychosis or Obsessions? Clozapine Associated with Worsening Obsessive-Compulsive Symptoms.

Authors:  Jonathan G Leung; Brian A Palmer
Journal:  Case Rep Psychiatry       Date:  2016-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.